AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 82 min read$GILD

Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)

Myriad Genetics (MYGN) reported Q2 revenue of $190.7M, down 10.5% YoY, missing estimates. It lowered full-year guidance, causing its stock to drop 20.7%. Amgen (AMGN) reported $10.05B in Q2 revenue, up 9.5% YoY, beating estimates. Novavax (NVAX) reported $56.7M in Q2 revenue, down 76.3% YoY, but beat EPS estimates. Both AMGN and NVAX stocks rose post-earnings.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 6:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD) — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$GILDNeutralLow
01

Why it matters

Mixed earnings outcomes create sector rotation opportunities.

02

Market read

Earnings recap provides limited new trading ideas; focus on Amgen and Novavax for potential upside, Myriad for downside.

03

What to watch

Potential pipeline updates or upcoming regulatory decisions not covered.

Relevance 4/10Novelty 2/10Timing: none

Background

Quarterly earnings for three therapeutic companies are recapped; Gilead appears only in title.

Company-level read

Ticker impact

$GILDNeutralLow confidence
Context

Title mentions Gilead Sciences; article focuses on therapeutic stocks sector.

Expected impact

likely little movement as no company-specific catalyst

Evidence & confidence

GILD is only in title, no new facts disclosed.

$MYGNBearishMedium confidence
Context

Myriad Genetics reported Q2 revenue miss and weak guidance, stock down 20.7%.

Expected impact

likely further pressure as market prices in weak outlook

Evidence & confidence

Revenue miss and guidance downgrade are fresh facts.

$AMGNBullishMedium confidence
Context

Amgen posted revenue beat and raised full‑year guidance, stock up 5.8%.

Expected impact

likely continued buying as investors digest beat

Evidence & confidence

Positive earnings surprise and guidance lift are fresh.

$NVAXBullishMedium confidence
Context

Novavax reported revenue decline but beat EPS estimates, stock up 45.1%.

Expected impact

potential upside as market focuses on earnings beat

Evidence & confidence

EPS beat is a fresh positive catalyst despite revenue fall.

Market effects

Sector

Therapeutics sector shows mixed earnings; investors may rotate between winners and laggards.

Regional

U.S. biotech stocks may see divergent moves based on individual results.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

Despite Amgen's beat, valuation may be stretched; caution on over‑buying.

Key entities

  • Company
    Myriad Genetics

    Biotech firm with revenue miss and weak guidance.

  • Company
    Amgen

    Biotech leader with earnings beat and raised guidance.

  • Company
    Novavax

    Vaccine maker with revenue decline but EPS beat.

  • Company
    Gilead Sciences

    Mentioned in title only.

Read at source← All news

Related articles

OCT 15
$GILDHighAI 9/10

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

finance.yahoo.com2 min
OCT 14
$VIRHighAI 9/10

Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

finance.yahoo.com2 min
OCT 14
$VIRHighAI 8/10

Vir Biotechnology partners with Gilead on cancer therapies

Vir Biotechnology (VIR) and Gilead Sciences (GILD) announced a collaboration to develop cancer therapies. VIR will receive $90M upfront, with potential milestones up to $1.74B. VIR will handle discovery, while GILD will develop and commercialize the therapies. The deal focuses on T-cell engagers targeting solid tumors.

investing.com2 min
OCT 14
$AMGNHighAI 8/10

Wall Street Falls as Hot US Inflation Fuels Fed Rate Hike Bets

Wall Street indices fell Wednesday after hotter-than-expected US inflation data raised Fed rate hike bets. S&P 500, Nasdaq, and Dow Jones declined. CPI rose 0.6% month-over-month, with annual inflation at 3.7%. Tech shares dropped, while healthcare stocks gained. Treasury yields initially surged but later retreated. Corporate earnings from Bank of America, Morgan Stanley, and BlackRock influenced sentiment.

econotimes.com3 min